Pharmacoeconomic Aspects of Diabetes Mellitus: Outcomes and Analysis
of Health Benefits Approach

Suman      Baishnab; Ravinder   Singh   Jaura; Saksham      Sharma; Honey      Garg; Thakur   Gurjeet   Singh
Abstract

Pharmacoeconomics is an important tool for investigating and restructuring healthcare policies. In India, recent statistical studies have shown that the number of diabetic patients is rapidly increasing in the rural, middle and upper-class settings. The aim of this review is to call attention towards the need to carry out pharmacoeconomic studies for diabetes mellitus and highlight the outcome of these studies on healthcare.
A well-structured literature search from PubMed, Embase, Springer, ScienceDirect, and Cochrane was done. Studies that evaluated the cost-effectiveness of various anti-diabetic agents for type 2 diabetes were eligible for inclusion in the analysis and review. Two independent reviewers sequentially assessed the titles, abstracts, and full articles to select studies that met the predetermined inclusion and exclusion criteria for data abstraction. Any discrepancies between the reviewers were resolved through consensus.
By employing search terms such as pharmacoeconomics, diabetes mellitus, cost-effective analysis, cost minimization analysis, cost-utility analysis, and cost-benefit analysis, a total of 194 papers were gathered. Out of these, 110 papers were selected as they aligned with the defined search criteria and underwent the removal of duplicate entries.
This review outlined four basic pharmacoeconomic studies carried out on diabetes mellitus. It gave a direction that early detection, patient counseling, personalized medication, appropriate screening intervals, and early start of pharmacotherapy proved to be a cost-effective as well as health benefits approach.
Keywords: Pharmacoeconomics, diabetes, cost analysis, healthcare, diabetes mellitus, pivotal importance.
[1]
Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford university press 2015.

[2]
Sanchez LA. Pharmacoeconomics and formulary decision making. PharmacoEconomics  1996; 9 (Suppl. 1): 16-25.
 [http://dx.doi.org/10.2165/00019053-199600091-00005] [PMID: 10160112]

[3]
Zaheer-Ud-Din B, Scahill S. Is there a role for pharmacoeconomics in developing countries? PharmacoEconomics  2010; 28(12): 1069-74.
 [http://dx.doi.org/10.2165/11584890-000000000-00000] [PMID: 21080732]

[4]
NICE U. Guide to the methods of technology appraisal. National Institute for Health and Clinical Excellence (NICE) London, UK- 2013. Available from: https://www.nice.org.uk/process/pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781 (Accessedon: March 21, 2021).

[5]
CADTH. Guidelines for the economic evaluation of health technologies: Canada.  Available from: www.cadth.ca/about-cadth/how-we-do-it/methods-and-guidelines/guidelines-for-the-economic-evaluation-of-health-technologies-canada (Accessed on: March 21, 2021).

[6]
Oberoi S, Oberoi A. Pharmacoeconomics guidelines: The need of hour for India. Int J Pharm Investig  2014; 4(3): 109-11.
 [http://dx.doi.org/10.4103/2230-973X.138338] [PMID: 25126523]

[7]
Simpson SH, Lier DA, Majumdar SR, et al. Cost-effectiveness analysis of adding pharmacists to primary care teams to reduce cardiovascular risk in patients with Type 2 diabetes: results from a randomized controlled trial. Diabet Med  2015; 32(7): 899-906.
 [http://dx.doi.org/10.1111/dme.12692] [PMID: 25594919]

[8]
Starostina EG, Antsiferov M, Galstyan GR, et al. Effectiveness and cost-benefit analysis of intensive treatment and teaching programmes for Type 1 (insulin-dependent) diabetes mellitus in Moscow—blood glucose versus urine glucose self-monitoring. Diabetologia  1994; 37(2): 170-6.
 [http://dx.doi.org/10.1007/s001250050089] [PMID: 8163051]

[9]
Alefan Q, Al-Issa ET, Alzoubi KH, Hammouri HM. Association of smoking with direct medical expenditures of chronic diseases in north of Jordan: a retrospective cohort study. BMJ Open  2019; 9(10): e031143.
 [http://dx.doi.org/10.1136/bmjopen-2019-031143] [PMID: 31601593]

[10]
Haddix AC, Teutsch SM, Corso PS, Eds. Prevention effectiveness: a guide to decision analysis and economic evaluation. Oxford University Press 2002.

[11]
Haddix AC, Teutsch SM, Corso PS, Eds. Prevention effectiveness: a guide to decision analysis and economic evaluation. Oxford University Press 2002.

[12]
Dilokthornsakul P, Kengkla K, Saokaew S, et al. An updated cost-effectiveness analysis of pneumococcal conjugate vaccine among children in Thailand. Vaccine  2019; 37(32): 4551-60.
 [http://dx.doi.org/10.1016/j.vaccine.2019.06.015] [PMID: 31280944]

[13]
Herman WH, Horblyuk R, Arondekar B, et al. PDB21 health care resource utilization and cost in type-2 diabetes patients receiving combination Sulfonylurea (Su) And Rosiglitazone (Rsg): The result trial. Value Health  2005; 8(3): 358.
 [http://dx.doi.org/10.1016/S1098-3015(10)62954-3]

[14]
Costa Pinel B, Belmonte Serrano M, Páez Vives F, Sabaté Obiol A, Estopá Sánchez A, Borrás Borrás J. Conversion of fast insulin intensive therapy to lispro insulin in type I diabetes. Pharmacoeconomic analysis of cost-effectiveness. Rev Clin Esp  2001; 201(8): 448-54.
 [http://dx.doi.org/10.1016/S0014-2565(01)70877-6] [PMID: 11599156]

[15]
Tang Z, Cai W. Cost-effectiveness of pharmacogenomics-guided drug therapy. Pharmacogenomics in precision medicine: From a Perspective of Ethnic Differences.   2020; pp. 241-55.
 [http://dx.doi.org/10.1007/978-981-15-3895-7_13]

[16]
Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet  2012; 380(9859): 2095-128.
 [http://dx.doi.org/10.1016/S0140-6736(12)61728-0] [PMID: 23245604]

[17]
Zhang N, Yang X, Zhu X, Zhao B, Huang T, Ji Q. Type 2 diabetes mellitus unawareness, prevalence, trends and risk factors: National Health and Nutrition Examination Survey (NHANES) 1999–2010. J Int Med Res  2017; 45(2): 594-609.
 [http://dx.doi.org/10.1177/0300060517693178] [PMID: 28415936]

[18]
Haghdoost AA, Rezazadeh Kermani M, Sadghirad B, Baradaran HR. Prevalence of type 2 diabetes in the Islamic Republic of Iran: Systematic review and meta-analysis. East Mediterr Health J  2009; 15(3): 591-9.
 [http://dx.doi.org/10.26719/2009.15.3.591]

[19]
Shah JV, Patni KN, Deshpande SS. Achieving Glycemic Control of Diabetic Patients through Clinical Pharmacist provided Counseling. Journal of Pharmaceutical Science and Bioscientific Research  2015; 5(4): 322-7.

[20]
Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: a pathophysiologic approach. Connecticut: Appleton and Lange  2014; 4: 141-2.

[21]
Bott OJ, Hoffmann I, Bergmann J, et al. Simulation based cost-benefit analysis of a telemedical system for closed-loop insulin pump therapy of diabetes. Stud Health Technol Inform  2006; 124: 435-40.
 [PMID: 17108558]

[22]
Shah JV, Patni KN, Deshpande SS. Pharmacoeconomic evaluation, cost minimization analysis of anti-diabetic therapy in Gujarat. Int J Med Res Health Sci  2016; 5(3): 34-43.

[23]
Haycox A. Basics of economics, health economics and Pharmacoeconomics içinde Walley, T, Haycox, A, Boland, APharmacoeconomics. London: Churchill Livingstone 2004.

[24]
Rascati K. Essentials of pharmacoeconomics. Lippincott Williams & Wilkins 2013.

[25]
Gu S, Tang Z, Shi L, Sawhney M, Hu H, Dong H. Cost-minimization analysis of metformin and acarbose in treatment of type 2 diabetes. Value Health Reg Issues  2015; 6: 84-8.
 [http://dx.doi.org/10.1016/j.vhri.2015.03.012] [PMID: 29698199]

[26]
Fragozo A, Puerta MF, Misas JD. Comparative analysis of insulin glargine vs. insulin detemir: A cost-minimization study applicable to Colombia. Biomédica  2015; 35(2): 204-11.
 [http://dx.doi.org/10.7705/biomedica.v35i2.2338] [PMID: 26535542]

[27]
Palmer AJ, Dinneen S, Gavin JR III, Gray A, Herman WH, Karter AJ. DN2 cost-utility analysis in a UK setting of self monitoring of blood glucose in patients with type-2 DIAbetes. Value Health  2005; 8(6): A14-5.
 [http://dx.doi.org/10.1016/S1098-3015(10)67184-7]

[28]
Adibe MO, Aguwa CN, Ukwe CV. Cost-utility analysis of pharmaceutical care intervention versus usual care in management of Nigerian patients with type 2 diabetes. Value Health Reg Issues  2013; 2(2): 189-98.
 [http://dx.doi.org/10.1016/j.vhri.2013.06.009] [PMID: 29702864]

[29]
Dawoud D, Fenu E, Higgins B, Wonderling D, Amiel SA. Basal insulin regimens for adults with type 1 diabetes mellitus: a cost-utility analysis. Value Health  2017; 20(10): 1279-87.
 [http://dx.doi.org/10.1016/j.jval.2017.05.021] [PMID: 29241887]

[30]
Davies MJ, Chubb BD, Smith IC, Valentine WJ. Cost–utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabet Med  2012; 29(3): 313-20.
 [http://dx.doi.org/10.1111/j.1464-5491.2011.03429.x] [PMID: 21883438]

[31]
Gao L, Zhao FL, Li SC. Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China. Int J Technol Assess Health Care  2012; 28(4): 436-44.
 [http://dx.doi.org/10.1017/S0266462312000608] [PMID: 23006540]

[32]
Vijan S, Hofer TP, Hayward RA. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. JAMA  2000; 283(7): 889-96.
 [http://dx.doi.org/10.1001/jama.283.7.889] [PMID: 10685713]

[33]
Ben ÂJ, Neyeloff JL, de Souza CF, et al. Cost-utility analysis of opportunistic and systematic diabetic retinopathy screening strategies from the perspective of the Brazilian public healthcare system. Appl Health Econ Health Policy  2020; 18(1): 57-68.
 [http://dx.doi.org/10.1007/s40258-019-00528-w] [PMID: 31674001]

[34]
Kim SW, Kang GW. Cost-utility analysis of screening strategies for diabetic retinopathy in Korea. J Korean Med Sci  2015; 30(12): 1723-32.
 [http://dx.doi.org/10.3346/jkms.2015.30.12.1723] [PMID: 26713046]

[35]
Xie X, Vondeling H. Cost-utility analysis of intensive blood glucose control with metformin versus usual care in overweight type 2 diabetes mellitus patients in Beijing, P.R. China. Value Health  2008; 11 (Suppl. 1): S23-32.
 [http://dx.doi.org/10.1111/j.1524-4733.2008.00363.x] [PMID: 18387063]

[36]
Chien CL, Chen YC, Malone DC, Peng YL, Ko Y. Cost-utility analysis of second-line anti-diabetic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin. Curr Med Res Opin  2020; 36(10): 1619-26.
 [http://dx.doi.org/10.1080/03007995.2020.1815686] [PMID: 32851879]

[37]
Men P, Qu S, Song Z, Liu Y, Li C, Zhai S. Lixisenatide for type 2 diabetes mellitus patients inadequately controlled on oral antidiabetic drugs: a mixed-treatment comparison meta-analysis and cost–utility analysis. Diabetes Ther  2020; 11(8): 1745-55.
 [http://dx.doi.org/10.1007/s13300-020-00857-3] [PMID: 32562244]

[38]
Pollock RF, Norrbacka K, Cameron C, Mancillas-Adame L, Jeddi M. A cost–utility analysis of dulaglutide versus insulin glargine as third-line therapy for type 2 diabetes in Canada. J Comp Eff Res  2019; 8(4): 229-40.
 [http://dx.doi.org/10.2217/cer-2018-0073] [PMID: 30644328]

[39]
Cloete L, Mitchell BG, Morton D. Protocol: investigating the effectiveness and cost benefit of a lifestyle intervention targeting type 2 diabetes in Australia. BMC Endocr Disord  2019; 19(1): 74.
 [http://dx.doi.org/10.1186/s12902-019-0396-x] [PMID: 31307434]

[40]
Gray A, Clarke P, Farmer A, Holman R. Implementing intensive control of blood glucose concentration and blood pressure in type 2 diabetes in England: cost analysis (UKPDS 63). BMJ  2002; 325(7369): 860.
 [http://dx.doi.org/10.1136/bmj.325.7369.860] [PMID: 12386035]

[41]
Gray A, Raikou M, McGuire A, et al. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). BMJ  2000; 320(7246): 1373-8.
 [http://dx.doi.org/10.1136/bmj.320.7246.1373] [PMID: 10818026]

[42]
Cavassini ACM, Lima SAM, Calderon IMP, Rudge MVC. Cost-benefit of hospitalization compared with outpatient care for pregnant women with pregestational and gestational diabetes or with mild hyperglycemia, in Brazil. Sao Paulo Med J  2012; 130(1): 17-26.
 [http://dx.doi.org/10.1590/S1516-31802012000100004] [PMID: 22344355]

[43]
Haardt MJ, Selam JL, Slama G, et al. A cost-benefit comparison of intensive diabetes management with implantable pumps versus multiple subcutaneous injections in patients with type I diabetes. Diabetes Care  1994; 17(8): 847-51.
 [http://dx.doi.org/10.2337/diacare.17.8.847] [PMID: 7956629]

[44]
Elixhauser A, Kitzmiller JL, Weschler JM. Short-term cost benefit of pre-conception care for diabetes. Diabetes Care  1996; 19(4): 384.
 [http://dx.doi.org/10.2337/diacare.19.4.384a] [PMID: 8729166]

[45]
Jadhav NB, Bhosale MS, Adhav CV. Cost analysis study of oral antidiabetic drugs available in Indian market. Int J Med Res Health Sci  2013; 2(1): 63-9.

[46]
Dranitsaris G, Longo CJ, Grossman LD. The economic value of a new insulin preparation, Humalog Mix 25. Measured by a willingness-to-pay approach. PharmacoEconomics  2000; 18(3): 275-87.
 [http://dx.doi.org/10.2165/00019053-200018030-00007] [PMID: 11147394]

[47]
Deng L, White AS, Pawlowska M, et al. Cost-benefit analysis of internet therapeutic intervention on patients with diabetes. Int J Endocrinol Metab  2015; 13(2): e22803.
 [http://dx.doi.org/10.5812/ijem.22803] [PMID: 25926853]

[48]
Katon W, Unützer J, Fan MY, et al. Cost-effectiveness and net benefit of enhanced treatment of depression for older adults with diabetes and depression. Diabetes Care  2006; 29(2): 265-70.
 [http://dx.doi.org/10.2337/diacare.29.02.06.dc05-1572] [PMID: 16443871]

[49]
Ji Y, Cao H, Liu Q, et al. Screening for pulmonary tuberculosis in high-risk groups of diabetic patients. Int J Infect Dis  2020; 93: 84-9.
 [http://dx.doi.org/10.1016/j.ijid.2020.01.019] [PMID: 31978585]

[50]
Guillermin AL, Samyshkin Y, Wright D, Nguyen T, Villeneuve J. Modeling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis. J Med Econ  2011; 14(2): 207-16.
 [http://dx.doi.org/10.3111/13696998.2011.561390] [PMID: 21361858]

[51]
Gu X, Liu F, Men P, Zhai S. Cost-effectiveness analysis of liraglutide versus insulin glargine in Chinese patients with type 2 diabetes insufficiently controlled on metformin. Value Health  2018; 21: S75.
 [http://dx.doi.org/10.1016/j.jval.2018.04.502]

[52]
Russo M, Bitran R, Rodriguez JC, Grassi B, Aguilera P. Cost minimization analysis of insulin glargine 300 u/ml vs. glargine 100 u/ml for the management of type 2 diabetes from a private and public third-party payer perspective in Chile. Value Health  2018; 21: S75-6.
 [http://dx.doi.org/10.1016/j.jval.2018.04.506]

[53]
Napoli R, Fanelli F, Gazzi L, Larosa M, Bitonti R, Furneri G. Using 2nd generation basal insulins in type 2 diabetes: Costs and savings in a comparative economic analysis in Italy, based on the BRIGHT study. Nutr Metab Cardiovasc Dis  2020; 30(11): 1937-44.
 [http://dx.doi.org/10.1016/j.numecd.2020.07.005] [PMID: 32912786]

[54]
Ravasio R, Pisarra P, Porzio R, Comaschi M. Economic evaluation of canagliflozin versus glimepiride and sitagliptin in dual therapy with metformin for the treatment of type 2 diabetes in Italy. Global & Regional Health Technology Assessment  2016; 3(2): GRHTA-5000229.
 [http://dx.doi.org/10.5301/GRHTA.5000229]

[55]
Abs M, Ghae E, Rawash A, Abo Taleb A. Cost minimization analysis of u100 insulin and u40 insulin in Egyptian diabetic patients. Value Health  2014; 17(7): A745.
 [http://dx.doi.org/10.1016/j.jval.2014.08.166] [PMID: 27202694]

[56]
Oksuz E, Malhan S, Urganci B, Tetik E. Cost-minimization analysis of linagliptin compared to sitagliptin in the treatment of type 2 diabetes mellitus from a Turkish healthcare perspective. J Diabetes Metab  2017; 8(5): 739.
 [http://dx.doi.org/10.4172/2155-6156.1000739]

[57]
Scherbaum WA, Goodall G, Erny-Albrecht KM, Massi-Benedetti M, Erdmann E, Valentine WJ. Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective. Cost Eff Resour Alloc  2009; 7(1): 9.
 [http://dx.doi.org/10.1186/1478-7547-7-9] [PMID: 19416529]

[58]
Henriksson F, Brandt A, Thomander L, Kielhorn A, Jansen R, Maniadakis N. PDG6: Cost-effectiveness of pioglitazone (Actos®, Takeda) in the management of type 2 diabetes mellitus in Sweden. Value Health  2001; 4(6): 504.
 [http://dx.doi.org/10.1016/S1098-3015(11)71743-0]

[59]
Ikeda S, Kobayashi M. PDB2 cost-effectiveness analysis of glycemic control with pioglitazone hydrochloride for Japanese patients with type ii diabetes. Value Health  2002; 5(6): 545.
 [http://dx.doi.org/10.1016/S1098-3015(10)61439-8]

[60]
Jansen R, Clausen JO, Maniadakis N, Kielhorn A, Brandt A. PDG14: an assessment of the costeffectiveness of pioglitazone (Actos*nf, Takeda) in type 2 diabetes mellitus in Denmark. Value Health  2001; 4(6): 507-8.
 [http://dx.doi.org/10.1016/S1098-3015(11)71751-X]

[61]
Murthy RK, DeLong LK, Chen SC. Critical appraisal of pharmacoeconomic studies. In: Williams HC, Bigby M, Herxheimer A, Eds. Evidence-Based Dermatology. 
 [http://dx.doi.org/10.1002/9781118357606.ch14]

[62]
WU J. Cost-effectiveness analysis of insulin aspart 30 versus insulin glargine in patients with type 2 diabetes in China. Chung Kuo Yao Hsueh Tsa Chih  2016; 242-7.

[63]
Cookson R, Mirelman AJ, Griffin S, et al. Using cost-effectiveness analysis to address health equity concerns. Value Health  2017; 20(2): 206-12.
 [http://dx.doi.org/10.1016/j.jval.2016.11.027] [PMID: 28237196]

[64]
Sun X, Guo L, Shang H, et al. The cost-effectiveness analysis of JinQi Jiangtang tablets for the treatment on prediabetes: a randomized, double-blind, placebo-controlled, multicenter design. Trials  2015; 16(1): 496.
 [http://dx.doi.org/10.1186/s13063-015-0990-9] [PMID: 26530718]

[65]
Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health  2014; 17(1): 5-14.
 [http://dx.doi.org/10.1016/j.jval.2013.08.2291] [PMID: 24438712]

[66]
Marshall DA, Douglas PR, Drummond MF, et al. Guidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada. PharmacoEconomics  2008; 26(6): 477-95.
 [http://dx.doi.org/10.2165/00019053-200826060-00003] [PMID: 18489199]

[67]
van de Vooren K, Duranti S, Curto A, Garattini L. A critical systematic review of budget impact analyses on drugs in the EU countries. Appl Health Econ Health Policy  2014; 12(1): 33-40.
 [http://dx.doi.org/10.1007/s40258-013-0064-7] [PMID: 24158922]

[68]
Kahn R, Alperin P, Eddy D, et al. Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet  2010; 375(9723): 1365-74.
 [http://dx.doi.org/10.1016/S0140-6736(09)62162-0] [PMID: 20356621]

[69]
Kirkizlar E, Serban N, Sisson JA, Swann JL, Barnes CS, Williams MD. Evaluation of telemedicine for screening of diabetic retinopathy in the Veterans Health Administration. Ophthalmology  2013; 120(12): 2604-10.
 [http://dx.doi.org/10.1016/j.ophtha.2013.06.029] [PMID: 24084501]

[70]
Nguyen HV, Finkelstein EA, Mital S, Gardner DSL. Incremental cost-effectiveness of algorithm-driven genetic testing versus no testing for Maturity Onset Diabetes of the Young (MODY) in Singapore. J Med Genet  2017; 54(11): 747-53.
 [http://dx.doi.org/10.1136/jmedgenet-2017-104670] [PMID: 28835481]

[71]
Klarenbach S, Cameron C, Singh S, Ur E. Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin. CMAJ  2011; 183(16): E1213-20.
 [http://dx.doi.org/10.1503/cmaj.110178] [PMID: 21969406]

[72]
Charokopou M, McEwan P, Lister S, et al. The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of type 2 diabetes mellitus. Diabet Med  2015; 32(7): 890-8.
 [http://dx.doi.org/10.1111/dme.12772] [PMID: 25817050]

[73]
Gordon J, McEwan P, Evans M, Puelles J, Sinclair A. Managing glycaemia in older people with type 2 diabetes: A retrospective, primary care-based cohort study, with economic assessment of patient outcomes. Diabetes Obes Metab  2017; 19(5): 644-53.
 [http://dx.doi.org/10.1111/dom.12867] [PMID: 28026911]

[74]
Zhang X, Liu S, Li Y, Wang Y, Tian M, Liu G. Long-term effectiveness and cost-effectiveness of metformin combined with liraglutide or exenatide for type 2 diabetes mellitus based on the CORE diabetes model study. PLoS One  2016; 11(6): e0156393.
 [http://dx.doi.org/10.1371/journal.pone.0156393] [PMID: 27304904]

[75]
Cherla A, Renwick M, Stefanini G, Holmes DR Jr, Mossialos E. Cost‐Effectiveness of Cardiovascular, Obesity, and Diabetes Mellitus Drugs: Comparative Analysis of the United States and England. J Am Heart Assoc  2020; 9(21): e018281.
 [http://dx.doi.org/10.1161/JAHA.120.018281] [PMID: 33121302]

[76]
Roberts S, Barry E, Craig D, Airoldi M, Bevan G, Greenhalgh T. Preventing type 2 diabetes: systematic review of studies of cost-effectiveness of lifestyle programmes and metformin, with and without screening, for pre-diabetes. BMJ Open  2017; 7(11): e017184.
 [http://dx.doi.org/10.1136/bmjopen-2017-017184] [PMID: 29146638]

[77]
Tzanetakos C, Melidonis A, Verras C, Kourlaba G, Maniadakis N. Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled type 2 diabetes on oral antidiabetic drugs in Greece. BMC Health Serv Res  2014; 14(1): 419.
 [http://dx.doi.org/10.1186/1472-6963-14-419] [PMID: 25245666]

[78]
Tzanetakos C, Tentolouris N, Kourlaba G, Maniadakis N. Cost-effectiveness of dapagliflozin as add-on to metformin for the treatment of type 2 diabetes mellitus in Greece. Clin Drug Investig  2016; 36(8): 649-59.
 [http://dx.doi.org/10.1007/s40261-016-0410-2] [PMID: 27221806]

[79]
Yokoyama KK, Griffin KC, Godley PJ, Cryar AK, Woodward BW. PDB9: Cost-effectiveness analysis of a multidisciplinary diabetes care clinic. Value Health  2001; 4(2): 115.
 [http://dx.doi.org/10.1046/j.1524-4733.2001.40202-126.x]

[80]
Chen S, Shaheen A, Garber A. Cost-effectiveness and cost-benefit analysis of using methotrexate vs. Goeckerman therapy for psoriasis. A pilot study. Arch Dermatol  1998; 134(12): 1602-8.
 [http://dx.doi.org/10.1001/archderm.134.12.1602] [PMID: 9875201]

[81]
Ozawa S, Clark S, Portnoy A, Grewal S, Brenzel L, Walker DG. Return on investment from childhood immunization in low-and middle-income countries, 2011–20. Health Aff (Millwood)  2016; 35(2): 199-207.
 [http://dx.doi.org/10.1377/hlthaff.2015.1086] [PMID: 26858370]

[82]
Bloom DE, Brenzel L, Cadarette D, Sullivan J. Moving beyond traditional valuation of vaccination: Needs and opportunities. Vaccine  2017; 35 (Suppl. 1): A29-35.
 [http://dx.doi.org/10.1016/j.vaccine.2016.12.001] [PMID: 28017436]

[83]
Laxminarayan R, Jamison DT, Krupnick AJ, Norheim OF. Valuing vaccines using value of statistical life measures. Vaccine  2014; 32(39): 5065-70.
 [http://dx.doi.org/10.1016/j.vaccine.2014.07.003] [PMID: 25045822]

[84]
Treasury HM. The green book: Central government guidance on appraisal and evaluation  Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/938046/The_Green_Book_2020.pdf (Accessed on: March 22, 2021).

[85]
Guidelines for Regulatory Impact Analysis 2016. Available from: https://aspe.hhs.gov/system/files/pdf/242926/HHS_RIAGuidance.pdf (Accessed on: March 22, 2021).

[86]
United States Environmental Protection Agency (EPA). Guidelines for Preparing Economic Analyses 2010. Available from: https://www.epa.gov/environmental-economics/guidelines-preparing-economic-analyses (Accessed on: March 22, 2021).

[87]
Elixhauser A, Weschler JM, Kitzmiller JL, et al. Cost-benefit analysis of preconception care for women with established diabetes mellitus. Diabetes Care  1993; 16(8): 1146-57.
 [http://dx.doi.org/10.2337/diacare.16.8.1146] [PMID: 8375245]

[88]
Smith I, Palmer AJ, Roze S, Kennedy-Martin T. PDB3 Cost-effectiveness analysis of insulin detemir compared to nph insulin in patients with type-2 diabetes in the United Kingdom. Value Health  2004; 7(6): 735-6.
 [http://dx.doi.org/10.1016/S1098-3015(10)65946-3]

[89]
Davey P, Grainger D, MacMillan J, Rajan N, Aristides M, Dobson M. Economic evaluation of insulin lispro versus neutral (regular) insulin therapy using a willingness-to-pay approach. PharmacoEconomics  1998; 13(3): 347-58.
 [http://dx.doi.org/10.2165/00019053-199813030-00009] [PMID: 10178660]

[90]
Al-Haddad M, Ibrahim MM, Sulaiman SA, Shafie AA, Maarup N. Cost benefit analysis of the diabetes self-management program at a University Health Centre in Malaysia. J Clin Diagn Res  2010; 4: 2521-30.

[91]
Matz H, Falk M, Göttinger W, Kieselbach G. Cost-benefit analysis of diabetic eye disease. Ophthalmologica  1996; 210(6): 348-53.
 [http://dx.doi.org/10.1159/000310742] [PMID: 8887393]

[92]
Taylor S, Hourihan F, Krass I, Armour C. Measuring consumer preference for models of diabetes care delivered by pharmacists. Pharm Pract (Granada)  2009; 7(4): 195-204.
 [http://dx.doi.org/10.4321/S1886-36552009000400002] [PMID: 25136394]

[93]
Thomas D, Hiligsmann M, John D, Al Ahdab OG, Li H. Pharmacoeconomic Analyses and Modeling. In: Thomas D, Ed. Clinical Pharmacy Education. 
 [http://dx.doi.org/10.1016/B978-0-12-814276-9.00018-0]

[94]
Wolowacz S, Pearson I, Shannon P, et al. Development and validation of a cost-utility model for type 1 diabetes mellitus. Diabet Med  2015; 32(8): 1023-35.
 [http://dx.doi.org/10.1111/dme.12663] [PMID: 25484028]

[95]
Zhong Y, Lin PJ, Cohen JT, Winn AN, Neumann PJ. Cost-utility analyses in diabetes: a systematic review and implications from real-world evidence. Value Health  2015; 18(2): 308-14.
 [http://dx.doi.org/10.1016/j.jval.2014.12.004] [PMID: 25773567]

[96]
Sortsø C, Green A, Jensen PB, Emneus M. Societal costs of diabetes mellitus in Denmark. Diabet Med  2016; 33(7): 877-85.
 [http://dx.doi.org/10.1111/dme.12965] [PMID: 26414087]

[97]
Brod M, Christensen T, Thomsen TL, Bushnell DM. The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health  2011; 14(5): 665-71.
 [http://dx.doi.org/10.1016/j.jval.2011.02.001] [PMID: 21839404]

[98]
Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet  2014; 53(9): 787-800.
 [http://dx.doi.org/10.1007/s40262-014-0165-y] [PMID: 25179915]

[99]
Meneghini L, Atkin SL, Gough SCL, et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: A 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care  2013; 36(4): 858-64.
 [http://dx.doi.org/10.2337/dc12-1668] [PMID: 23340894]

[100]
Mathieu C, Hollander P, Miranda-Palma B, et al. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab  2013; 98(3): 1154-62.
 [http://dx.doi.org/10.1210/jc.2012-3249] [PMID: 23393185]

[101]
Kadowaki T, Jinnouchi H, Kaku K, Hersløv ML, Hyllested-Winge J, Nakamura S. Efficacy and safety of once‐daily insulin degludec dosed flexibly at convenient times vs fixed dosing at the same time each day in a Japanese cohort with type 2 diabetes: A randomized, 26‐week, treat‐to‐target trial. J Diabetes Investig  2016; 7(5): 711-7.
 [http://dx.doi.org/10.1111/jdi.12502] [PMID: 27182031]

[102]
Pollock RF, Tikkanen CK. A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark. J Med Econ  2017; 20(3): 213-20.
 [http://dx.doi.org/10.1080/13696998.2016.1245663] [PMID: 27705031]

[103]
Geng J, Yu H, Mao Y, Zhang P, Chen Y. Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes. PharmacoEconomics  2015; 33(6): 581-97.
 [http://dx.doi.org/10.1007/s40273-015-0266-y] [PMID: 25736235]

[104]
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med  2015; 373(22): 2117-28.
 [http://dx.doi.org/10.1056/NEJMoa1504720] [PMID: 26378978]

[105]
Nguyen E, Coleman CI, Nair S, Weeda ER. Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk. J Diabetes Complications  2018; 32(2): 210-5.
 [http://dx.doi.org/10.1016/j.jdiacomp.2017.10.006] [PMID: 29157870]

[106]
Berger ML, Bingefors K, Hedblom EC, Pashos CL, Torrance GW. Health Care Cost, Quality, and Outcomes. Lawrenceville, NJ: ISPOR Book of Terms 2003.

[107]
Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: the importance of rigorous methods. BMJ  1996; 313(7048): 36-9.
 [http://dx.doi.org/10.1136/bmj.313.7048.36] [PMID: 8664772]

[108]
Greene WL, Concato J, Feinstein AR. Claims of equivalence in medical research: are they supported by the evidence? Ann Intern Med  2000; 132(9): 715-22.
 [http://dx.doi.org/10.7326/0003-4819-132-9-200005020-00006] [PMID: 10787365]

[109]
Span MM, TenVergert EM, van der Hilst CS, Stolk RP. Noninferiority testing in cost-minimization studies: Practical issues concerning power analysis. Int J Technol Assess Health Care  2006; 22(2): 261-6.
 [http://dx.doi.org/10.1017/S0266462306051099] [PMID: 16571203]

[110]
Billings LK, Doshi A, Gouet D, et al. Efficacy and safety of IDegLira versus basal-bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin: the DUAL VII randomized clinical trial. Diabetes Care  2018; 41(5): 1009-16.
 [http://dx.doi.org/10.2337/dc17-1114] [PMID: 29483185]

[111]
Torre E, Bruno GM, Di Matteo S, et al. Cost-minimization analysis of degludec/liraglutide versus glargine/aspart: economic implications of the DUAL VII study outcomes. Clinicoecon Outcomes Res  2018; 10: 413-21.
 [http://dx.doi.org/10.2147/CEOR.S169045] [PMID: 30100746]

[112]
Salas M, Hughes D, Zuluaga A, Vardeva K, Lebmeier M. Costs of medication nonadherence in patients with diabetes mellitus: A systematic review and critical analysis of the literature. Value Health  2009; 12(6): 915-22.
 [http://dx.doi.org/10.1111/j.1524-4733.2009.00539.x] [PMID: 19402848]

[113]
Garg N, Arunan SK, Arora S, Kaur K. Application of mobile technology for disease and treatment monitoring of gestational diabetes mellitus among pregnant women: A systematic review. J Diabetes Sci Technol  2022; 16(2): 491-7.
 [http://dx.doi.org/10.1177/1932296820965577] [PMID: 33118397]

[114]
Singh R, Kumari P, Prashar A, Sardana O, Singh V. Assessment of medication adherence among type-2 diabetes mellitus in a tertiary care hospital of North India. Environ Sci Pollut Res Int  2022; 29(17): 24951-5.
 [http://dx.doi.org/10.1007/s11356-021-17434-1] [PMID: 34826085]
Cite As
Current Diabetes Reviews

Pharmacoeconomic Aspects of Diabetes Mellitus: Outcomes and Analysis of Health Benefits Approach

Abstract
